While some targets are chosen because of their functional relevance to AML pathogenesis (CD5, CD33, CD36), others are of particular interest due to their relatively upregulated expression on AML cells or potency in pre-clinical trials (CD44, CD64, CD123). Here, CD33 is linked to acute myeloid leukemia.